| Ulcerative colitis treatment patterns and cost of care KD Null, Y Xu, MK Pasquale, C Su, A Marren, J Harnett, J Mardekian, ... Value in Health 20 (6), 752-761, 2017 | 41 | 2017 |
| Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients RK Mahabaleshwarkar, Y Yang, MV Datar, JP Bentley, MW Strum, ... Current medical research and opinion 29 (4), 315-323, 2013 | 23 | 2013 |
| Retrospective claims analysis indirectly comparing medication adherence and persistence between intravenous biologics and oral small-molecule therapies in inflammatory bowel … K Moran, K Null, Z Huang, T Lissoos, S Kane Advances in Therapy 36, 2260-2272, 2019 | 20 | 2019 |
| Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat R Sheer, KD Null, KA Szymanski, L Sudharshan, J Banovic, MK Pasquale ClinicoEconomics and Outcomes Research, 629-639, 2017 | 16 | 2017 |
| Health care costs and resource utilization among patients with Crohn’s disease with and without perianal fistula G Chen, V Pedarla, KD Null, SE Cazzetta, QR Khan, DA Schwartz Inflammatory Bowel Diseases 28 (6), 870-877, 2022 | 12 | 2022 |
| Development and validation of an inflammatory bowel disease severity index using US administrative claims data: a retrospective cohort study G Chen, T Lissoos, C Dieyi, KD Null Inflammatory Bowel Diseases 27 (8), 1177-1183, 2021 | 10 | 2021 |
| Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease K Null, V Kumar, T Lissoos, M Luo Journal of Medical Economics 21 (11), 1102-1109, 2018 | 5 | 2018 |
| Trends associated with implementing and lifting a pregabalin step therapy policy KD Null, K Moll, A Sadosky, MK Pasquale, JC Cappelleri, B Parsons American Journal of Health Benefits 8, e17-e24, 2016 | 3 | 2016 |
| Discontinuation of Corticosteroids among Ulcerative Colitis Patients Treated with Vedolizumab in the United States (US) H Patel, B Chastek, KD Null, D Demuth Gastroenterology 152 (5), S396-S397, 2017 | 2 | 2017 |
| Real-World Treatment Persistence with Vedolizumab in Crohn's Disease and Ulcerative Colitis Patients in the United States (US): A Retrospective Analysis Using the Optum … D Demuth, H Patel, B Chastek, B Lee, JM Khalid, KD Null Official journal of the American College of Gastroenterology| ACG 111, S324, 2016 | 2 | 2016 |
| PIH34 IMPLEMENTATION OF A STATE MEDICAID PRESCRIPTION CAP POLICY: IS THERE AN IMPACT ON BENEFICIARIES'MEDICAL SERVICES UTILIZATION AND COSTS? R Khanna, SH Dharmarajan, KD Null, JP Bentley, PF Pace, BF Banahan Value in Health 14 (3), A111-A111, 2011 | 2 | 2011 |
| Pgi4 retrospective study of dose escalation with adalimumab, infliximab, and vedolizumab in the treatment of inflammatory bowel disease KH Zhang, H Singh, R Twardowski, C Lu, Y Wan, K Null Value in Health 23, S143, 2020 | 1 | 2020 |
| Su1019-Adherence and Persistence with Vedolizumab Among Patients with Inflammatory Bowel Disease in an Academic Medical Center KD Null, HL Chang, T Lissoos, M Luo, B Cohen, BE Sands, A Atreja Gastroenterology 154 (6), S-456-S-457, 2018 | 1 | 2018 |
| Su1008-A Comparison of Medication Adherence and Persistence Between Intrevenous Biologics and Oral Small-Molecule Therapies SV Kane, K Moran, KD Null, Z Huang, T Lissoos Gastroenterology 154 (6), S-452-S-453, 2018 | 1 | 2018 |
| P525 Adherence and persistence with vedolizumab among patients with inflammatory bowel disease in an academic medical centre K Null, HL Chang, T Lissoos, M Luo, B Cohen, BE Sands, A Atreja Journal of Crohn's and Colitis 12 (supplement_1), S371-S372, 2018 | 1 | 2018 |
| Discontinuation of Corticosteroids among Crohn's Disease Patients Treated with Vedolizumab in the United States (US) H Patel, B Chastek, KD Null, D Demuth Gastroenterology 152 (5), S397, 2017 | 1 | 2017 |
| Real-World Treatment Persistence with Vedolizumab in Patients with Ulcerative Colitis and Crohn's Disease: A Retrospective Claims Analysis in the US: 718 KD Null, J Visaria, D Demuth, H Patel, S Zhou, T Lissoos, M Luo Official journal of the American College of Gastroenterology| ACG 111, S322-S324, 2016 | 1 | 2016 |
| Assessing the impact of varying threshold criteria for Opioid Overutilization M Durkin, K Moll, MK Pasquale, T Amos, KD Null Value in Health 18 (3), A306-A307, 2015 | 1 | 2015 |
| PRS39 Palavizumab (Synagis) Use and Outcomes Among Medicaid Beneficiaries M Datar, BF Banahan, KD Null, SP Hardwick, JP Clark Value in Health 15 (4), A58-A59, 2012 | 1 | 2012 |
| PMH2 RISK OF HOSPITALIZATION FOR PNEUMONIA ASSOCIATED WITH THE USE OF ATYPICAL VERSUS TYPICAL ANTIPSYCHOTICS IN A NATIONAL SAMPLE OF MEDICARE BENEFICIARIES SH Dharmarajan, Y Yang, AS Athavale, JP Bentley, KD Null, BF Banahan Value in Health 14 (3), A185-A185, 2011 | 1 | 2011 |
Vennela ThumulaPolicy Analyst, Workers Compensation Research InstituteVerified email at wcrinet.org
